The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression

被引:86
作者
Kelley, Todd W.
Pohlman, Brad
Elson, Paul
Hsi, Eric D.
机构
[1] Cleveland Clin, Dept Clin Pathol, Cleveland, OH 44195 USA
[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
[3] Cleveland Clin, Taussig Canc Ctr, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44195 USA
关键词
FOXP3; regulatory T-cells; granzyme B; cytotoxic T/NK cells; Hodgkin lymphonna; bcl-2; MAL;
D O I
10.1309/NB3947K383DJ0LQ2
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We studied the prognostic importance of tumor-infiltrating regulatory T lymphocytes (Tregs) and cytotoxic T/NK lymphocytes (CTLs) in 98 diagnostic biopsy specimens from patients with classical Hodgkin lymphoma (cHL). Immunohistochemical analysis was performed for FOXP3 to identify Tregs and for granzyme B (GrB) to identify activated CTLs. Failure-free survival (FFS) and overall survival (OS) were clinical end points. Patients with fewer than 25 FOXP3+ cells per high-power field (HPF) had a mean +/- SD 5-year FFS of 64% +/- 7% vs 85% +/- 5%,for patients with 25 or more FOXP3+ cells/HPF (P =.05). A FOXP3/GrB ratio of 1 or less was associated with poor FFS (46% +/- 10% vs 86% +/- 4%; P <.001) and OS (67% +/- 10% vs 93% +/- 3%; P <.001). When prior available MAL and bcl-2 expression data were included in a multivariate analysis of all clinical and biologic factors, a FOXP3/GrB ratio of 1 or less and tumor cell expression of MAL and bcl-2 all independently predicted poor FFS. This demonstrates the importance of evaluating tumor cell markers and the tumor immune infiltrate when considering biologic prognostic markers in cHL.
引用
收藏
页码:958 / 965
页数:8
相关论文
共 34 条
[1]   Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].
Alvaro, T ;
Lejeune, M ;
Salvadó, MT ;
Bosch, R ;
García, JF ;
Jaén, J ;
Banham, AH ;
Roncador, G ;
Montalbán, C ;
Piris, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1467-1473
[2]   Defective regulatory and effector T cell functions in patients with FOXP3 mutations [J].
Bacchetta, Rosa ;
Passerini, Laura ;
Gambineri, Eleonora ;
Dai, Minyue ;
Allan, Sarah E. ;
Perroni, Lucia ;
Dagna-Bricarelli, Franca ;
Sartirana, Claudia ;
Matthes-Martins, Susanne ;
Lawitschka, Anita ;
Azzari, Chiara ;
Ziegler, Steven F. ;
Levings, Megan K. ;
Roncarolo, Maria Grazia .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (06) :1713-1722
[3]   Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells [J].
Barao, I ;
Hanash, AM ;
Hallett, W ;
Welniak, LA ;
Sun, K ;
Redelman, D ;
Blazar, BR ;
Levy, RB ;
Murphy, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (14) :5460-5465
[4]   Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells [J].
Dave, SS ;
Wright, G ;
Tan, B ;
Rosenwald, A ;
Gascoyne, RD ;
Chan, WC ;
Fisher, RI ;
Braziel, RM ;
Rimsza, LM ;
Grogan, TM ;
Miller, TP ;
LeBlanc, M ;
Greiner, TC ;
Weisenburger, DD ;
Lynch, JC ;
Vose, J ;
Armitage, JO ;
Smeland, EB ;
Kvaloy, S ;
Holte, H ;
Delabie, J ;
Connors, JM ;
Lansdorp, PM ;
Ouyang, Q ;
Lister, TA ;
Davies, AJ ;
Norton, AJ ;
Muller-Hermelink, HK ;
Ott, G ;
Campo, E ;
Montserrat, E ;
Wilson, WH ;
Jaffe, ES ;
Simon, R ;
Yang, LM ;
Powell, J ;
Zhao, H ;
Goldschmidt, N ;
Chiorazzi, M ;
Staudt, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21) :2159-2169
[5]   Cutting edge:: Contact-mediated suppression by CD4+-CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism [J].
Gondek, DC ;
Lu, LF ;
Quezada, SA ;
Sakaguchi, S ;
Noelle, RJ .
JOURNAL OF IMMUNOLOGY, 2005, 174 (04) :1783-1786
[6]   A prognostic score for advanced Hodgkin's disease [J].
Hasenclever, D ;
Diehl, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1506-1514
[7]   Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma [J].
Hedvat, CV ;
Hegde, A ;
Chaganti, RSK ;
Chen, BY ;
Qin, J ;
Filippa, DA ;
Nimer, SD ;
Teruya-Feldstein, J .
HUMAN PATHOLOGY, 2002, 33 (10) :968-974
[8]   Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease [J].
Herbst, H ;
Foss, HD ;
Samol, J ;
Araujo, I ;
Klotzbach, H ;
Krause, H ;
Agathanggelou, A ;
Niedobitek, G ;
Stein, H .
BLOOD, 1996, 87 (07) :2918-2929
[9]   MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis [J].
Hsi, ED ;
Sup, SJ ;
Alemany, C ;
Tso, E ;
Skacel, M ;
Elson, P ;
Alonso, MA ;
Pohlman, B .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (05) :776-782
[10]  
Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3